For: | Yokoo H, Takahashi H, Hagiwara M, Iwata H, Imai K, Saito Y, Matsuno N, Furukawa H. Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report. World J Hepatol 2020; 12(12): 1349-1357 [PMID: 33442460 DOI: 10.4254/wjh.v12.i12.1349] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v12/i12/1349.htm |
Number | Citing Articles |
1 |
Junichi Shindoh, Yusuke Kawamura, Masahiro Kobayashi, Norio Akuta, Satoshi Okubo, Masaru Matsumura, Yoshiyuki Suzuki, Masaji Hashimoto. Prognostic Advantages of Individual Additional Interventions After Lenvatinib Therapy in Patients with Advanced Hepatocellular Carcinoma. Journal of Gastrointestinal Surgery 2022; doi: 10.1007/s11605-022-05388-9
|
2 |
Yoshifumi Hidaka, Miyo Tomita, Ryosuke Desaki, Masahiro Hamanoue, Sonshin Takao, Mari Kirishima, Takao Ohtsuka. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report. World Journal of Surgical Oncology 2022; 20(1) doi: 10.1186/s12957-022-02691-2
|
3 |
Yutaka Endo, Motohide Shimazu, Tadayuki Sakuragawa, Yusuke Uchi, Motonori Edanami, Ken Sunamura, Soji Ozawa, Naokazu Chiba, Shigeyuki Kawachi. Successful treatment with laparoscopic surgery and sequential multikinase inhibitor therapy for hepatocellular carcinoma: A case report. World Journal of Gastrointestinal Surgery 2022; 14(3): 260-267 doi: 10.4240/wjgs.v14.i3.260
Abstract(84) |
Core Tip(80) |
Full Article(HTML)(621)
|
Full Article (PDF)-5489K(105)
|
Full Article (Word)-2259K(13)
|
Audio-1916K(0)
|
Peer-Review Report-258K(14)
|
Answering Reviewers-52K(18)
|
Times Cited (0)
|
Total Visits (1745)
|
Open
|
4 |
Atsushi Naganuma, Yuhei Suzuki, Takashi Hoshino, Hidetoshi Yasuoka, Yuki Tamura, Hiroaki Naruse, Hiroshi Tanaka, Keitaro Hirai, Ichiro Sakamoto, Tetsushi Ogawa, Takeshi Hatanaka, Satoru Kakizaki. A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy. Clinical Journal of Gastroenterology 2022; 15(1): 177 doi: 10.1007/s12328-021-01558-5
|
5 |
Yoh Asahi, Toshiya Kamiyama, Tatsuhiko Kakisaka, Tatsuya Orimo, Shingo Shimada, Akihisa Nagatsu, Takeshi Aiyama, Yuzuru Sakamoto, Hirofumi Kamachi, Akinobu Taketomi. Outcomes of reduction hepatectomy combined with postoperative multidisciplinary therapy for advanced hepatocellular carcinoma. World Journal of Gastrointestinal Surgery 2021; 13(10): 1245-1257 doi: 10.4240/wjgs.v13.i10.1245
Abstract(109) |
Core Tip(112) |
Full Article(HTML)(534)
|
Full Article (PDF)-1954K(67)
|
Full Article (Word)-190K(35)
|
Audio-1783K(0)
|
Peer-Review Report-206K(26)
|
Answering Reviewers-193K(24)
|
Times Cited (0)
|
Total Visits (1964)
|
Open
|
6 |
Shinji Itoh, Katsuya Toshida, Kazutoyo Morita, Takeshi Kurihara, Yoshihiro Nagao, Takahiro Tomino, Takeo Toshima, Noboru Harada, Masaki Mori, Tomoharu Yoshizumi. Clinical effectiveness of surgical treatment after lenvatinib administration for hepatocellular carcinoma. International Journal of Clinical Oncology 2022; doi: 10.1007/s10147-022-02229-2
|
7 |
Kensuke Yamamura, Toru Beppu. Conversion surgery for hepatocellular carcinoma after multidisciplinary treatment including lenvatinib. Hepatology Research 2021; 51(10): 1029 doi: 10.1111/hepr.13691
|
8 |
Junichi Arita, Akihiko Ichida, Rihito Nagata, Yuichiro Mihara, Yoshikuni Kawaguchi, Takeaki Ishizawa, Nobuhisa Akamatsu, Junichi Kaneko, Kiyoshi Hasegawa. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors. Journal of Hepato-Biliary-Pancreatic Sciences 2022; 29(7): 732 doi: 10.1002/jhbp.1135
|